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BACKGROUND: Insulin-like growth factor (IGF)-I signalling stimulates proliferation, survival, and invasion in malignant mesothelioma and
other tumour types. Studies have found that tumourigenesis is linked to dysregulation of cap-dependent protein translation.
METHODS: The effect of IGF stimulation on cap-mediated translation activation in mesothelioma cell lines was studied using binding
assays to a synthetic 7-methyl GTP-cap analogue. In addition, cap-mediated translation was genetically repressed in these cells with a
dominant active motive of 4E-BP1.
RESULTS: In most mesothelioma cell lines, IGF-I stimulation resulted in a hyperphosphorylation-mediated inactivation of 4E-BP1
compared with that in normal mesothelial cells. An inhibitor of Akt diminished IGF-I-mediated phosphorylation of 4E-BP1, whereas
inhibiting MAPK signalling had no such effect. IGF-I stimulation resulted in the activation of the cap-mediated translation complex as
indicated by an increased eIF4G/eIF4E ratio in cap-affinity assays. Akt inhibition reversed the eIF4G/eIF4E ratio. Mesothelioma cells
transfected with an activated 4E-BP1 protein (4E-BP1
A37/A46) were resistant to IGF-I-mediated growth, motility, and colony
formation. In a murine xenograft model, mesothelioma cells expressing the dominant active 4E-BP1
A37/A46 repressor protein showed
abrogated tumourigenicity compared with control tumours.
CONCLUSION: IGF-I signalling in mesothelioma cells drives cell proliferation, motility, and tumourigenesis through its ability to activate
cap-mediated protein translation complex through PI3K/Akt/mTOR signalling.
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Malignant mesothelioma is an aggressive cancer arising from the
serosal lining of the pleural or peritoneal cavity. Along with
asbestos exposure, simian virus 40 infection has been implicated in
the development of mesothelioma. Despite attempts to treat
mesothelioma with multimodal therapies, estimates of median
survival are usually less than 1 year (Whitson and Kratzke, 2006;
Lee et al, 2007). In the United States, nearly 3000 deaths are
attributed to mesothelioma annually (Britton, 2002). The patho-
genesis of mesothelioma involves multiple-signalling pathways,
including vascular endothelial growth factor, epidermal growth
factor, wnt, and insulin-like growth factor-I (IGF-I) (Whitson and
Kratzke, 2006; Lee et al, 2007). A recent study has also
demonstrated that both the Ras/mitogen-activated protein kinase
(MAPK) pathway and the phosphatidylinositol 30 kinase (PI3K)/
Akt pathway are activated in mesothelioma cells compared with
non-transformed mesothelial cells (Patel et al, 2007). Many studies
have found that the risk of developing several common cancers is
linked to elevated levels of circulating IGF-I, as well as to an
increased ratio of IGF-I to inhibitory-binding proteins (reviewed
in (Jerome et al, 2003)). An array-based study found the presence
of altered transcript profiles of genes from the IGF-I axis (Hoang
et al, 2004a). In a follow-up study, mRNA levels of 12 components
of the IGF-I axis were elevated in mesothelioma cells compared
with that in a mesothelial cell line (Hoang et al, 2004b). Four
mRNA levels, in particular, were increased: IGF-I (43.3-fold),
insulin receptor substrate (IRS)-2 (24.0-fold), IRS-1 (4.4-fold), and
IGF1R (2.6-fold). This suggests that an activated IGF-I axis
contributes to the malignant phenotype of mesothelioma. In
addition, the activation of IGF1R adaptor proteins (IRS-1 and IRS-
2) has been shown to contribute to the proliferative or motility
phenotype of mesothelioma cells. These previous studies along
with others (Lee et al, 1993) demonstrate the importance of the
IGF-I system in the pathogenesis of mesothelioma.
In normal cells, IGF-I binds to IGF1R and activates its kinase
activity, leading to the targeting of its corresponding adaptor
proteins, including IRS-1, IRS-2, and SHC. These substrates
initiate phosphorylation cascades, resulting in the activation of
the extracellular signal-regulated kinase (ERK) 1/2 and PI3K/Akt
pathways and leading to cell proliferation and survival (reviewed
in (Sachdev and Yee, 2006), (Haddad and Yee, 2006)). Among the
probable downstream targets of these pathways is the cap-
mediated translation complex. In IGF-I-driven cancers, it is highly
probable that the cancer-specific effects of IGF1R activation
are mediated in part through the activation of cap-mediated
translation.
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tumourigenesis in multiple tumour types (Jacobson et al, 2006),
including mesothelioma (Patel et al, 2007). The rate-limiting step
in the initiation of mRNA translation is the binding of eukaryotic
initiation factor 4E (eIF4E) to the 50-cap structure (m7GpppN) of
mRNA. Overexpression of eIF4E is observed in many solid
tumours. Under normal cellular conditions, eIF4E is negatively
regulated by 4E-BP proteins. 4E-BP1 blocks the interaction
between eIF4E and the scaffolding protein eIF4G, inhibiting the
formation of the active eIF4F complex and suppressing
cap-mediated translation. 4E-BP1 undergoes hierarchical phos-
phorylation during mitogenic stimulation, which decreases its
affinity for eIF4E and results in the activation of translation
(De Benedetti and Graff, 2004; Polunovsky and Bitterman, 2006).
In cancer, elevated levels of active eIF4F increase the translation of
‘‘weak’’ mRNAs with long structured 50-untranslated regions,
which typically encode anti-apoptotic proteins and growth
regulatory factors contributing to tumourigenesis (Graff and
Zimmer, 2003; Thumma and Kratzke, 2007).
This study examines the importance of cap-dependent
translation in mediating the effects of the IGF-I axis in
mesothelioma. Evidence is presented establishing the fact that
activation of both PI3K and ERK1/2 pathways after IGF-I
stimulation leads to a stimulation of the eIF4F complex.
Furthermore, a dominant active 4E-BP1 results in the repression
of translation and disrupts IGF-I-mediated motility and prolifera-
tion of mesothelioma cells. Expression of the dominant active 4E-
BP1 resulted in significantly decreased tumourigenicity of murine
xenografts. These results demonstrate that the malignant pheno-
type and tumourigenicity conferred upon mesothelioma by the
IGF-I pathway is dependent upon the activation of cap-dependent
translation.
MATERIALS AND METHODS
Cell lines and cell culture
Mesothelioma cell lines were obtained from either the American
Type Culture Collection or from Frederick Kaye (NCI). The
medium used for H513, H2052, H2373, H2461, and H2596 was
RPMI (Gibco, Invitrogen, Carlsbad, CA, USA), containing 10% calf
serum (Biofluids, Rockville, MD, USA). LP9 cells, a non-
transformed human mesothelial cell line, were obtained from the
National Institute on Aging Cell Repository at passage five. They
were maintained in a medium containing a 1:1 ratio of M199 and
MCDB10 basal medium (Sigma), supplemented with 15% calf
serum, 10ngml
 1 EGF, and 0.4mgml
 1 hydrocortisone.
IGF-I stimulation was carried out on cells grown to 50%
confluence. Cells were washed twice with phosphate-buffered
saline (PBS) and grown in a serum-free medium (SFM) for 14–
16h. Also added at this time to the appropriate plates was the PI3K
inhibitor, LY294002 (Promega, Madison, WI, USA) (20mM), or the
MAPK kinase (MAPKK or MEK) inhibitor, U0126 (Promega)
(10mM). The medium was then replaced with fresh SFM containing
or not containing 5nM IGF-I (Gro Pep) for the indicated times and,
where indicated, fresh pathway inhibitors were also added. All cells
were maintained at 371Ci n5 %C O 2.
Cell lysate preparation
Cell lysate was prepared for the cap-affinity assays as follows: Cells
were washed with PBS, scraped from the plate in the presence of 1ml
PBS, centrifuged, and resuspended in five times the pellet volume of
freeze–thaw lysis buffer (50mM Tris-HCl pH 7.5, 150mM NaCl,
50mM NaF, 1mM EDTA, 10mM tetrasodium pyrophosphate),
supplemented with a protease inhibitor cocktail (Roche, Basel,
Switzerland) and a phosphatase inhibitor cocktail (Sigma). The cells
were subjected to three consecutive freeze (15min at  801C) and
thaw (2min at 371C) cycles, followed by centrifugation (14K r.p.m.,
41C) for 10min. For the purpose of studying membrane-bound
proteins, a second batch of cell lysate was prepared from cells
processed under identical conditions but in the detergent-containing
lysis buffer TNESV (50mM T r i s - H C l ,p H7 . 4 ;1 %N P - 4 0 ;2m M EDTA,
pH 8.0; 0.1 M NaCl), supplemented with both protease and
phosphatase inhibitors. Lysate protein concentrations were deter-
m i n e db yB r a d f o r da s s a ya n ds t o r e da t 801C.
Immunoblot analysis
Protein samples were separated by SDS-PAGE on either straight
15% or an 8–15% gradient (cap-affinity assay samples) and then
transferred to a PVDF membrane (Hybond-P, Amersham Bios-
ciences, Piscataway, NJ, USA). Membranes were blocked in 5%
non-fat dry milk for 1h at room temperature in Tris-buffered
saline Tween 20 (TBST: 0.15 M NaCl; 0.01 M Tris-HCl, pH 7.6; 0.05%
Tween 20), rinsed, and incubated for 1h at room temperature with
the appropriate primary antibody. Blots were probed separately
with either rabbit a-eIF4GI antibody (kindly provided by Nahum
Sonenberg, McGill University Montreal, Quebec, Canada) at a
1:2500 dilution, rabbit a-IGF1R antibody (Santa Cruz Biotechno-
logy Inc., Santa Cruz, CA, USA) at a 1:1000 dilution, rabbit a-
phospho-IGF1R antibody (Cell Signaling, Danvers, MA, USA) at a
1:1000 dilution, rabbit a-Akt antibody (Cell Signaling) at a 1:1000
dilution, rabbit a-phospho-Akt (ser473) antibody (Cell Signaling)
at a 1:1000 dilution, rabbit a-MAPK antibody (Cell Signaling) at a
1:1000 dilution, rabbit a-phospho-MAPK (Thr202/Tyr204) anti-
body (Cell Signaling) at a 1:1000 dilution, rabbit a-4E-BP1
antibody (Abcam Inc., Cambridge, MA, USA) at a 1:2500 dilution,
a-phospho-4E-BP1 (ser65) antibody (Cell Signaling) at a 1:1000
dilution, a-eIF4E antibody (BD Biosciences, San Jose, CA, USA) at
a 1:500 dilution, mouse a-actin (Sigma) at a 1:10000 dilution, or
rat a-HA antibody (Roche) at a 1:2000 dilution to detect the
haemagglutinin-tagged HA-4E-BP1
A37/A46 proteins. The blots were
washed thrice in TBST before incubation with appropriate
horseradish peroxidase-labeled secondary antibodies, followed by
incubation for 1h at room temperature and three more washes in
TBST. Bands of interest were visualised with the ECL Plus western
blotting system (Amersham Biosciences, Piscataway, NJ, USA).
The density of protein bands was determined using ImageJ, a
public domain Java image-processing programme.
Cell transfection
Mesothelioma cell lines were transfected with the plasmid
pACTAG-2 encoding the neomycin resistance gene or with
pACTAG neo/HA-4E-BP1
A37/A46. The cells were plated at 50%
confluence and transfected (Lipofectin reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA)) with 5mg of the appropriate
plasmid DNA. After 72h, the growth medium was replaced with
medium containing G-418 (Cellgro, Manassas, VA, USA)
(250mgml
 1). Resistant colonies were collected and transferred
to a fresh plate and propagated.
Cloning efficiency assay
Cell lines were transfected according to the procedure as described
above, with one exception. When resistant colonies were of
appropriate size, plates were fixed in 10% methanol and 5% acetic
acid for 10min, stained in 0.1% crystal violet/20% ethanol for
5min, and scored for G-418-resistant colonies as previously
described (Kratzke et al, 1995). All transfections were carried out
in triplicate.
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Cell motility was assessed by seeding 5 10
3 cells into coated wells
of BioCoat Invasion Chambers (BD Biosciences). Twenty-four
hours later, the cells were washed twice with PBS and cultured in
SFM with or without 5nM IGF-I. After 24h of incubation, the cells
remaining on the top of the membrane were removed with cotton
swabs, whereas cells migrating through the 8mm-sized pores onto
the opposite side of the membrane were fixed (100% methanol),
stained (0.1% crystal violet), and then counted microscopically. All
experiments were carried out in triplicate.
Cell proliferation assay
Cells were seeded as triplicate sets into 96-well plates with 6000 cells per
well for H2373, H2373 empty vector, and H2373 4E-BP1
A37/A46,a n d
with 3000 cells per well for H2461, H2461 empty vector, and H2461 4E-
BP1
A37/A46. After 24h, the cells were switched to SFM and incubated for
a n o t h e r2 4hi nt h ep r e s e n c eo ra b s e n c eo f5n M IGF-I. After incubation,
cell growth was measured using the Cell Counting Kit-8 (Dojindo
Molecular Technologies, Rockville, MD, USA) according to the
manufacturer’s protocol. At the appropriate time, 10mlo fr e a g e n t
was added to each well and incubated at 371C for 4h. Absorbance at
450nm for each well was read on a microplate reader. Each experiment
was repeated twice with similar results for each cell line.
In vitro cap-affinity assay
Cap-affinity assay was performed as before (Jacobson et al, 2006);
briefly, 300ml( 1mgml
 1) of cell lysate was incubated while mixing
for 2h at 41C with 50ml of suspended (50% mixture) 7-methyl
GTP-Sepharose4B (Amersham Biosciences) to capture eIF4E and
its binding partners, eIF4G and 4E-BP1. The captured proteins
were eluted with 35ml of elution buffer (25mM Tris-HCl pH 7.5,
150mM KCl) containing 100mM of 7-methylguanosine 50-tripho-
sphate (Sigma-Aldrich, St Louis, MO, USA) and were prepared for
immunoblotting.
Xenograft tumourigenicity assay
H2373 cells (2.1 10
7) stably transfected with pACTAG neo or
with pACTAG neo/HA-4E-BP1
A37/A46 were suspended in 0.5ml of
PBS and injected subcutaneously into the left or right flank,
respectively, of five nude mice (nu/nu; Harlan). Tumour formation
was quantified after 23 days by weight. Another set of five nude
mice were injected with 0.5ml of PBS containing H2596 cells
(2.6 10
7) stably transfected with pACTAG neo or pACTAG
neo/HA-4E-BP1
A37/A46 into the left or right flank, respectively.
Fourteen days after injection, the growth of these tumours was
quantified by weight. All animal experiments were carried out
under Institutional Animal Care and Use Committee of the
Department of Veteran Affairs Medical Center, which conforms
with the UKCCCR guidelines (Workman et al, 1998).
RESULTS
IGF-I-mediated inactivation of 4E-BP1 depends on Akt
signalling in mesothelioma
To assess the impact of IGF-I stimulation on the activation of
signalling pathways underlying the malignant phenotype, a panel
of mesothelioma cell lines and normal mesothelial cells were
treated with IGF-I (5nM) for varying times, followed by
immunoblot analysis. Treatment of IGF-I for 20min stimulated
the intrinsic tyrosine kinase activity of IGF1R, resulting in
phosphorylation in both mesothelioma cells and control LP9
mesothelial cells (Figure 1A). Increased IGF1R phosphorylation
lasted for up to 300min in two cell lines (H2461, H513), but drifted
back to baseline levels in the remaining mesothelioma cells
(H2373, H2052, and H2596) and control LP9 mesothelial cells. As
expected, total IGF1R levels did not change during the experiment.
As shown in earlier studies (Hoang et al, 2004b), MAPK and PI3K/
Akt were phosphorylated upon IGF-I stimulation for 20min in all
five of the mesothelioma cell lines and control mesothelial cells.
Peak levels of MAPK and Akt phosphorylation were reached at
20min in all mesothelioma cell lines, with the exception of H2596
cells, which peaked at 60min. Normal LP9 mesothelial cells had a
weaker response to IGF-I stimulation. Total Akt and MAPK
protein levels remained stable for both the LP9 control cells and
mesothelioma cell lines.
Sequential phosphorylation of 4E-BP1 leads to slower electro-
phoretic migration, with the g, b, and a isoforms corresponding,
respectively, to hyper-, intermediate, and hypophosphorylation.
After IGF-I stimulation, slow-migrating g and b isoforms of 4E-
BP1 were phosphorylated in a sustained manner even for up to
300min in most, but not all, of the mesothelioma cell lines
(Figure 1A). The percentage of hypophosphorylated 4E-BP1
decreased when mesothelioma cells were stimulated with IGF-I
(Figure 1B). These results reveal a direct correlation between IGF-I
stimulation and inactivation of the 4E-BP1 repressor protein.
The roles of Akt and MAPK pathways were investigated next to
delineate whether these pathways mediate an IGF-I-induced
inactivation of 4E-BP1 in mesothelioma. Akt inhibition with
LY294002 strongly diminished the phosphorylation of Akt and its
downstream target 4E-BP1 in all five mesothelioma cell lines and
control LP9 cells (Figure 1A and B). Although MAPK inhibition
with U0126 did suppress the phosphorylation of MAPK, it did not
suppress 4E-BP1 phosphorylation as expected (Figure 1A and B).
These results confirm that IGF-I-mediated inactivation of 4E-BP1
is dependent upon Akt/mTOR signalling. Finally, the level of
eIF4G, the scaffolding component of the eIF4F complex necessary
for the initiation of translation, was not affected by IGF-I
stimulation and was mildly decreased upon LY294002 treatment
in three of the five mesothelioma cell lines (H2052, H513, and
H2596) and LP9 cells (Figure 1A). It is known that eIF4G is cleaved
by caspase 3 during apoptosis induction. It is possible that
treatment with LY249002 decreased eIF4G levels by inducing
caspase-mediated cleavage (Prevot et al, 2003).
IGF-I stimulation activates the cap-mediated translation
complex in mesothelioma
On the basis of the findings that IGF-I stimulation promotes
phosphorylation of both 4E-BP1 and eIF4E, resulting in the
inactive and active forms of these proteins, respectively, it was
hypothesised that IGF-I stimulation of mesothelioma cells would
result in an enhanced eIF4F function and increased translation. To
examine the effects of IGF-I stimulation on cap-dependent
translation in mesothelioma, synthetic 7
mGTP-sepharose beads
were used to capture eIF4E and its binding partners, eIF4G and 4E-
BP1. Mesothelioma cells were treated with or without IGF-I, and
cap-binding assays were performed on cell lysate prepared in the
same manner as the assays described in Figure 1. Relatively higher
levels of cap-bound eIF4G in cell lysate signify the functional
potency of eIF4F, whereas higher levels of cap-captured 4E-BP1
indicate a repression of the eIF4F complex. Consistent with the
activation of the cap-mediated translation complex, the quantity of
eIF4E-bound eIF4G was increased in most mesothelioma cell lines
treated with IGF-I for 20 or 300min compared with that in
untreated cells (Figure 2A, top panel). Furthermore, 4E-BP1
binding decreased substantially (Figure 2A, lowest panel) in most
mesothelioma cells treated with IGF-I, indicating an inactivation of
4E-BP1 after phosphorylation. In response to IGF-I stimulation,
the ratio of eIF4G to eIF4E was increased 1.5- to 3.5-fold compared
with that in untreated cells (Figure 2B). The effect on cap-
dependent translation of activating 4E-BP1 by blocking the PI3K/
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using the cap-affinity assay. In all mesothelioma cell lines,
LY249002 treatment resulted in a decrease in the eIF4G/eIF4E
ratio in IGF-I-stimulated cells than in cells treated with only IGF-I
(Figure 2B). In some cell lines (H2373, H513, and H2596), the ratio
fell to levels at or below that of IGF-I-untreated cells. In addition,
the level of eIF4E-bound 4E-BP1 increased in IGF-I stimulated cells
treated with LY249002 (Figure 1A), consistent with the suppression
of cap-dependent translation.
Constitutively active 4E-BP1
A37/A46 inhibits activation of
the eIF4F complex in mesothelioma
If cap-mediated translation contributes to the malignant pheno-
type, then repressing its activity should repress the malignant
potential of mesothelioma cells. Mesothelioma cells were selected
to ectopically express active 4E-BP1 using a phosphorylation-
defective 4E-BP1
A37/A46. The 4E-BP1
A37/A46 construct has substi-
tuted alanine for threonine at residues 37 and 46, the first two sites
of sequential phosphorylation that render 4E-BP1 incapable of
phosphorylation and consequently dominantly active (Gingras
et al, 2001). To assess the ability of 4E-BP1
A37/A46 to interfere with
the assembly of the eIF4F initiation complex, a cap-analogue
capture of eIF4E and its binding partners was used, followed by
immunoblot analysis. Four mesothelioma cell lines were stably
transfected with an empty vector or with the same vector-
containing 4E-BP1
A37/A46. Expression of exogenously produced
4E-BP1
A37/A46 was present in cell lysate for all four cell lines
(Figure 3A, top panel). The HA-tagged ectopically expressed 4E-
BP1
A37/A46 migrates more slowly and is easily monitored (a-HA
antibody). For each mesothelioma cell line stably transfected with
empty vector, eIF4G avidly bound to eIF4E (Figure 3A, lower
panel), which is indicative of a translationally active state. For each
cell line, the association of eIF4G to eIF4E was repressed when cells
expressed 4E-BP1
A37/A46 compared with cells transfected with an
empty vector (Figure 3A, lower panel). Formation of the eIF4F
initiation complex was inhibited in cells expressing 4E-BP1
A37/A46
by 66.7% (H2373) to 51% (H2461) (Figure 3B). Results from the
cap-affinity assay show that the quantity of eIF4E bound to 4E-BP1
inversely correlates with the level of eIF4G bound to eIF4E
(Figure 3A). The level of the mutually exclusive cap-bound
proteins (eIF4G and 4E-BP1) indicates that ectopically
expressed 4E-BP1
A37/A46 strongly diminishes the activation of the
cap-dependent complex.
Constitutively active 4E-BP1
A37/A46 inhibits IGF-I-mediated
effects on mesothelioma
The previous results demonstrate that IGF-I stimulation of
mesothelioma cells directly promotes activation of the eIF4F
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Figure 1 IGF-I stimulation activates downstream-signalling pathways and inactivates 4E-BP1 in mesothelioma cell lines. (A) Immunoblot analysis showing
phosphorylation and total levels of proteins involved in cell-signalling pathways (IGF1R, Akt, and MAPK) or in initiation of translation (eIF4G, eIF4E, and 4E-
BP1) after treatment (in minutes) with and without IGF-I (5nM) or on treatment with IGF-I (5nM for 20min) combined with LY249002 (LY) or U0126 (U).
(B) Representation of the percentage of 4E-BP1 in hypophosphorylated isoforms (a, open columns) compared with that in hyperphosphorylated isoforms
(b þ g, filled columns) for mesothelioma cells and mesothelial control cells (LP9) not treated or treated with IGF-I (5nM) or IGF-I combined with LY249002
(LY) or U0126 (U) for the indicated times. b-actin represents loading controls for each cell line.
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mediated translation and mesothelioma cell cloning efficiency,
proliferation, motility, and tumourigenicity. Each of the four
mesothelioma cell lines was transfected with either the dominant
active 4E-BP1
A37/A46 gene or the empty vector. Colonies were
counted and normalised to that of the empty vector. In all four
mesothelioma cell lines, ectopically expressed 4E-BP1
A37/A46
exhibited a dramatic impact on cloning efficiency (Figure 4).
To assess the effects on motility and proliferation when cap-
mediated translation is repressed, mesothelioma cell lines were
stably transfected with empty vector or with the 4E-BP1
A37/A46
dominant active gene. Transfected cells and control parental cells
were grown in SFM in the presence or absence of IGF-I (Figure 5).
In both the parental and empty vector-containing cell lines, IGF-I
exposure led to increased proliferation compared with that in
untreated cells (Figure 5). 4E-BP1
A37/A46 expression resulted in
diminished proliferation. In a similar manner, 4E-BP1
A37/A46
expression decreased mesothelioma cell motility after IGF-I
stimulation (Figure 6), although the results did not reach statistical
significance. Parental and empty vector-containing H2461 cells
showed a 4- and 2.6-fold enhancement of cell migration,
respectively, when exposed to IGF-I than did untreated cells. In
contrast, the migration of H2461 cells expressing 4E-BP1
A37/A46 did
not increase in response to IGF-I stimulation. These results
demonstrate that the proliferative and migratory responses of
mesothelioma cells after IGF-I treatment are blunted by repressing
cap-mediated translation.
Constitutively active 4E-BP1
A37/A46 abrogates xenograft
tumour growth
The IGF-I stimulation of cap-mediated translation in mesothelio-
ma is ultimately only important if it contributes to the
tumourigenic potential of mesothelioma cells. To demonstrate
the relationship between cap-mediated translation and in vivo
tumour formation, H2596 or H2373 cells ectopically expressing 4E-
BP1
A37/A46 or empty vector were injected into nude mice. Animals
were killed, tumours were excised, and weighed on days 14 and 27
after implantation of H2596 and H2373 cells, respectively.
Expression of 4E-BP1
A37/A46 caused a marked suppression of
tumour growth in these mesothelioma xenografts (Figure 7B).
H2373 cells expressing 4E-BP1
A37/A46 produced tumours that were
one-third the size of parental controls. H2596 cells expressing 4E-
BP1
A37/A46 did not produce tumours in any mice. Lysate prepared
from H2373 cells expressing empty vector or 4E-BP1
A37/A46 was
subjected to immunoblot analysis both before and after implanta-
tion into mice (Figure 7A). The level of expression of the
4E-BP1
A37/A46 protein diminished during xenograft tumour growth
to a nearly undetectable level in H2373 xenograft tumours,
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Figure 4 Constitutively active 4E-BP1 hinders mesothelioma colony
formation. Mesothelioma cell lines were transfected with empty vector
(open columns) or HA-4E-BP1
A37/A46 (filled columns). G418-resistant
clones were counted for each transfection and normalised to the value for
empty vector transfection for each cell line.
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Figure 5 Abrogation of IGF-I-stimulated cell proliferation by a constitutively active 4E-BP1. H2373 and H2461 cell lines expressing dominant active
4E-BP1
A37/A46 in the presence or absence of IGF-I (5nM), and 24h later, cell growth was measured. Columns, the mean of three independent determinations
of cell number, bars, s.d.
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Figure 6 Suppression of IGF-I activated cell motility by disruption of cap-
mediated translation. H2461 cells that do and do not produce dominant
active 4E-BP1
A37/A46 in the presence (filled columns) or absence (open
columns) of IGF-I (5nM). After 24h incubation, cell migration was assayed.
Columns, the mean of three independent determinations of migrating cells,
bars, s.d.
Active translation repressor 4E-BP1 inhibits malignancy
BA Jacobson et al
429
British Journal of Cancer (2009) 101(3), 424–431 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssuggesting that tumour growth occurred after the selection of cells
expressing minimal levels of 4E-BP1
A37/A46. These results show
that suppression of aberrant cap-dependent translation in
mesothelioma cells abrogates tumour growth.
DISCUSSION
Activated cap-mediated protein translation is found in many
cancers (Mamane et al, 2004). This activation is associated with the
preferential translation of a limited number of transcripts
responsible for cell proliferation and survival (Graff and Zimmer,
2003; Rajasekhar et al, 2003). Enhanced cap-mediated translation
in cancer often occurs after either an overexpression of eIF4E,
phosphorylation of eIF4E, or an inactivation of the 4E-BP1
repressor protein. In mesothelioma, the primary mechanism for
elevated levels of cap-mediated translation seems to be a low-level
expression of the 4E-BP1 repressor protein in conjunction with an
activation of eIF4E (Patel et al, 2007). This is in contrast to
previous observations in cancers, such as non-small-cell lung
cancer, in which both elevated levels of eIF4E and inactivation of
the 4E-BP1 repressor protein are the primary mechanisms for
activating the eIF4F complex (Jacobson et al, 2006). This study
shows that IGF-I stimulation of mesothelioma cells results in
a similar hyperphosphorylation and inactivation of 4E-BP1
(Figure 1).
It is well known that IGF-I stimulation of eukaryotic cells can
lead to increased protein translation and contribute to the
malignant potential in a variety of cell types (Miller and Yee,
2005). In mesothelioma, IGF-I stimulation leads to the downstream
activation of both PI3K/Akt and MAPK pathways (Hoang et al,
2004b). The observation that IGF-I stimulation is associated with
increased phosphorylation of 4E-BP1, allowing for an increase in
the binding of the competing eIF4G protein, thus favouring protein
translation, is not unexpected and is consistent with IGF-I-driven
malignant growth in mesothelioma. In support of the function of
the IGF-I axis in mesothelioma development, previous data
demonstrate that malignant transformation of mesothelial cells
in animal models requires an intact IGF1R molecule (Pass et al,
1996). An intact and active IGF-I axis is necessary for both the
development and propagation of mesothelioma cells.
Activation of IGF1R is associated with an increase in both
mesothelioma cell proliferation and motility (Hoang et al, 2004b).
In this study, when cap-mediated protein translation
was suppressed using the dominantly active mutant protein,
4E-BP1
A37/A46, mesothelioma cells showed diminished prolifera-
tion and motility even under conditions of IGF-I stimulation. IGF-I
stimulation of mesothelioma cells also led directly to the activation
of the cap-mediated translation complex. The importance of
activation or repression of cap-mediated translation in meso-
thelioma is strongly emphasised by the observation that an
enforced repression of translation in mesothelioma cells resulted
in the near total loss of tumourigenic potential.
Our finding that cap-mediated protein translation is associated
with IGF-I stimulation suggests that IGF1R inhibition is a very
attractive therapeutic target in mesothelioma. IGF1R inhibitors are
currently in clinical testing and seem to have potent in vitro
activity against mesothelioma cells (Whitson et al, 2006). There are
data that these agents are synergistic with cytotoxic chemotherapy,
an observation that fits well with the pro-apoptotic effects known
to accompany a repression of cap-mediated translation. We have
previously shown that an enforced repression of cap-mediated
activity can render cancer cells more susceptible to chemo-
therapeutic-induced apoptosis in non-small-cell lung cancer cells
(Jacobson et al, 2006). Suppressing IGF1R activation should have
the same effect of reducing cap-mediated translation and
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Figure 7 Xenograft tumour growth is abrogated by constitutively active 4E-BP1. (A) tumour size for 10 animals (mean±s.e.) from cell lines H2373 and
H2596 expressing (filled columns) or not expressing (open columns) 4E-BP1
A37/A46. Columns, the mean of five xenograft measurements of each cell line, bars,
s.e. (B) immunoblot analysis of lysates from mesothelioma cells producing or not producing 4E-BP1
A37/A46 both before (in vitro) and after implantation
(xenograft) into the mice. The level of ectopic HA-tagged 4E-BP1 is shown.
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senhancing chemosensitivity. In addition, the IGF1R-mediated
activation of PI3K leads to an acquired resistance to gefitinib, an
epidermal growth factor receptor tyrosine kinase inhibitor, in
A431 lung cancer cells (Guix et al, 2008). The inhibition of both
EGFR and IGF1R was required to reverse acquired in vitro drug
resistance. It is tempting to speculate that both oncogenic
pathways converge upon the initiation of translation to mediate
their oncogenic effects. If so, the initiation of cap-dependent
translation would be an attractive target for new therapies, as it
would potentially block the downstream signal of two major
oncogenic pathways.
Novel agents are being developed for targeting eIF4E or for
disabling the eIF4F molecular complex as a potential cancer
therapy (Graff et al, 2007, 2008). On the basis of these data
demonstrating the important function that IGF-I stimulation and
cap-mediated protein translation have in the malignant potential
of mesothelioma cells, these therapies could prove to be promising
treatments for mesothelioma. In the light of the findings that the
effects of IGF1R activation in mesothelioma depend on the
activation of the eIF4F complex, it will be interesting to combine
IGF1R inhibition with agents designed to target cap-mediated
translation.
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